The usual Xhance (fluticasone ... infection with or without nasal polyps. The typical Xhance dosage for adults for this condition is either: 186 mcg twice daily (one spray per nostril twice ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

One of the most potent methods to soothe these allergy-induced symptoms is the use of an allergy nasal spray. An allergy nasal spray is a medication that is sprayed into the nose to relieve ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monotherapy for adults with major depressive ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

OKAY, HONEY, COME SIT HERE. TODAY, JOE IS TESTING SOMETHING NEW. A MEDICATION CALLED FOR INSIDE THIS NASAL SPRAY. ONE, TWO. THREE. JOE IS THE FIRST PATIENT WITH ALZHEIMER’S TO TRY THIS DRUG.